Rinatabart sesutecan (Rina-S)
Antibody–drug conjugate
Also known as PRO1184, GEN1184
Evidence outlook
Ovarian Cancer: topline reported 2026-10-23
The sponsor reported topline results on 2026-10-23 (Phase 3 RAINFOL-02 (NCT06619236) met PFS and key secondary OS). The announcement is listed under Regulatory events.
Latest reported trial: RAINFOL-02 (NCT06619236) · Phase 3 · met primary endpoint · grade pending
Also in development:Non-Small Cell Lung Cancer · Phase 2HR+/HER2- Metastatic Breast Cancer · Phase 1/2Endometrial Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RAINFOL-02 NCT06619236 · Ovarian Cancer Registry: NCT06619236 | 3 | Progression-Free Survival (PFS) (Up to approximately 1.5 years) 2026-08-18 | RAINFOL-02, ITT (n=584): PFS HR 0.29 (95% CI 0.23 to 0.37), p<0.0001 vs investigator's-choice chemotherapy; overall survival also significantly improved (Genmab topline, 2026-10-23). | not yet graded | link ↗ |
View 2 more trials
RAINFOL-07 NCT07564141 · Ovarian Cancer Registry: NCT07564141 | 3 | Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR) (Up to approximately 3 years) 2029-12 | In progress: results expected 1 Dec 2029 | not yet graded | link ↗ |
RAINFOL-04 NCT07225270 · Ovarian Cancer Registry: NCT07225270 | 3 | Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, as Determined by Blinded Independent Central Review (BICR) (Up to approximately 3 years) 2028-10 | In progress: results expected 1 Oct 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other Folate receptor alpha (FRα) drugs
Sofetabart mipitecan, Torvutatug samrotecan, ABBV-901, IMGN-151. Compare all 5 Folate receptor alpha (FRα) drugs
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Endometrial Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rinatabart Sesutecan (Rina-S): this drug | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Dostarlimab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023). | |
| Fruquintinib (Fruzaqla / Elunate) | Phase 3 | Small molecule | VEGFR1/2/3 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08634404 | Phase 3 | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Puxitatug Samrotecan | Phase 3 | Antibody–drug conjugate | B7-H4 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Govitecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Selinexor | Phase 3 | Small molecule | XPO1 (exportin-1) | not yet graded | No reviewed efficacy summary in this indication | |
| Sotiburafusp Alfa | Phase 3 | Multispecific antibody | PD-L1 / VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Pamirtecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Serabelisib | Phase 2 | Small molecule | PI3K alpha (inhibitor) | Weak signal | No reviewed efficacy summary in this indication | |
| IMGN-151 | Phase 1 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rinatabart sesutecan (Rina-S) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (3)
September 2028 (1)
What to watch
October 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (2)
2030 (1)
March 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent